IGC Pharma (IGC) Current Assets (2011 - 2026)

IGC Pharma (IGC) has reported Current Assets for 16 consecutive years, with $1.1 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Current Assets fell 60.39% year-over-year to $1.1 million in Q1 2026; TTM through Mar 2026 was $1.1 million, a 60.39% decrease from a year earlier, with the FY2026 full-year figure at $1.1 million, down 60.39% from the prior year.
• Current Assets was $1.1 million for Q1 2026 at IGC Pharma, down from $1.8 million in the prior quarter.
• Over five years, Current Assets peaked at $15.1 million in Q1 2022 and troughed at $1.1 million in Q1 2026.
• A 5-year average of $5.6 million and a median of $4.2 million in 2024 frame the typical range for Current Assets.
• Across the five-year window, Current Assets plunged 61.7% in 2023 and dropped 13.21% in 2024, its largest moves.
• Over 5 years, Current Assets stood at $9.4 million in 2022, then sank by 61.7% to $3.6 million in 2023, then fell by 14.85% to $3.1 million in 2024, then slumped by 41.33% to $1.8 million in 2025, then tumbled by 35.92% to $1.1 million in 2026.
• The last three Current Assets figures came in at $1.1 million (Q1 2026), $1.8 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.